See more : AUGROUP (2519.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Strongbridge Biopharma plc (SBBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Strongbridge Biopharma plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Tohokushinsha Film Corporation (2329.T) Income Statement Analysis – Financial Results
- ARA LOGOS Logistics Trust (K2LU.SI) Income Statement Analysis – Financial Results
- Wecon Holdings Limited (1793.HK) Income Statement Analysis – Financial Results
- Gibus S.p.A. (GBUS.MI) Income Statement Analysis – Financial Results
- QuantRx Biomedical Corporation (QTXB) Income Statement Analysis – Financial Results
Strongbridge Biopharma plc (SBBP)
About Strongbridge Biopharma plc
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 30.73M | 21.71M | 18.03M | 7.05M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.21M | 3.82M | 3.99M | 1.48M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 28.52M | 17.89M | 14.04M | 5.56M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 92.80% | 82.40% | 77.89% | 78.95% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 25.80M | 30.90M | 25.44M | 17.27M | 20.02M | 20.14M | 5.84M | 2.53M |
| General & Administrative | 40.87M | 45.81M | 63.34M | 36.29M | 14.88M | 22.72M | 4.59M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 40.87M | 45.81M | 63.34M | 36.29M | 14.88M | 22.72M | 4.59M | 0.00 |
| Other Expenses | 5.02M | 5.02M | 7.19M | 5.02M | 0.00 | 0.00 | 0.00 | -7.73M |
| Operating Expenses | 71.68M | 81.74M | 95.96M | 58.58M | 34.90M | 42.85M | 10.43M | -5.19M |
| Cost & Expenses | 73.90M | 85.56M | 99.95M | 60.07M | 34.90M | 42.85M | 10.43M | 5.19M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 25.00K | 0.00 | 0.00 |
| Interest Expense | 1.34M | 0.00 | 12.52M | 4.31M | 20.00K | 3.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 5.11M | 5.10M | 7.23M | 5.03M | 10.00K | 11.00K | 6.00K | 3.00K |
| EBITDA | -38.65M | -42.58M | 52.14M | -102.37M | -51.21M | -44.02M | -10.14M | -5.39M |
| EBITDA Ratio | -125.76% | -196.13% | 289.21% | -1,452.84% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -43.17M | -63.85M | -81.92M | -53.02M | -34.90M | -42.85M | -10.43M | -5.19M |
| Operating Income Ratio | -140.46% | -294.05% | -454.45% | -752.47% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.93M | 16.16M | 114.31M | -58.69M | -16.46M | -1.23M | 282.00K | -288.00K |
| Income Before Tax | -45.09M | -47.68M | 32.39M | -111.71M | -51.36M | -44.08M | -10.15M | -5.48M |
| Income Before Tax Ratio | -146.72% | -219.62% | 179.66% | -1,585.47% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -15.00K | 1.77M | 536.00K | 1.77M | -2.64M | -450.00K | -480.00K | -93.00K |
| Net Income | -45.08M | -49.45M | 31.85M | -113.48M | -48.60M | -43.58M | -9.67M | -5.30M |
| Net Income Ratio | -146.68% | -227.76% | 176.68% | -1,610.60% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.80 | -0.89 | 0.64 | -3.11 | -2.26 | -2.62 | -0.96 | -0.88 |
| EPS Diluted | -0.80 | -0.89 | 0.64 | -3.11 | -2.24 | -2.62 | -0.96 | -0.88 |
| Weighted Avg Shares Out | 56.11M | 55.38M | 49.72M | 36.54M | 21.55M | 16.61M | 10.11M | 6.02M |
| Weighted Avg Shares Out (Dil) | 56.11M | 55.38M | 49.72M | 36.54M | 21.66M | 16.61M | 10.11M | 6.02M |
Strongbridge Biopharma plc Announces New Employment Inducement Awards
Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update
Strongbridge Biopharma: $2.50 Biotech Stock Finally Seeing Some Momentum
Strongbridge Biopharma plc (SBBP) CEO John Johnson on Q3 2020 Results - Earnings Call Transcript
Strongbridge Biopharma plc Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Strongbridge Biopharma's Recorlev Phase 3 Topline Data Due September 2020 Is A Major Value Inflection Point (NASDAQ:SBBP)
Source: https://incomestatements.info
Category: Stock Reports